ArticleTherapeutic advances in medical oncology2023
A phase Ia dose-escalation trial of Ametumumab (a fully human monoclonal antibody against epidermal growth factor receptor) in patients with advanced solid malignancies.
Da Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.